Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
- 30 January 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 22 (3), 349-356
- https://doi.org/10.1097/qad.0b013e3282f4709a
Abstract
We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression. All patients achieving an undetectable viral load while on therapy were followed until viral rebound or the time of the last viral load. Poisson regression was used to describe the independent impact of treatment interruptions on rebound rates. A total of 12 977 patients from the United Kingdom Collaborative HIV Cohort (UK CHIC) Study achieved a viral load of less than 50 copies/ml. These patients contributed a total of 37 314 person-years of follow-up. The overall rebound rate was 8.07 (7.78, 8.36) per 100 person-years. In adjusted analyses, rates of viral rebound were up to 64% higher (rate ratio 1.64; 1.43, 1.88) in those who had previously interrupted therapy compared with those who had not. Patients who had interrupted at detectable viral loads had up to a 74% (1.74; 1.42, 2.14) higher chance of rebounding compared with those who had not interrupted with a detectable viral load. We found no evidence to suggest interrupting treatment at an undetectable viral load was associated with viral rebound. Among patients with an undetectable viral load, having previously interrupted therapy while the viral load was detectable is associated with a raised risk of rebound.This publication has 24 references indexed in Scilit:
- Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatmentJournal of Infection, 2007
- Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patientsAIDS, 2007
- CD4+ Count–Guided Interruption of Antiretroviral TreatmentThe New England Journal of Medicine, 2006
- CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialThe Lancet, 2006
- Treatment interruptions in HIV-infected subjectsJournal of Antimicrobial Chemotherapy, 2006
- CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trialThe Lancet, 2006
- Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infectionJournal of Antimicrobial Chemotherapy, 2005
- Discontinuation of Antiretroviral Therapy in Patients with Chronic HIV Infection: Clinical, Virologic, and Immunologic ConsequencesAIDS Patient Care and STDs, 2005
- Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptionsAIDS, 2002
- Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyNature Medicine, 1999